Market closed
Verastem/$VSTM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
$VSTM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
73
Website
Verastem Metrics
BasicAdvanced
$186M
Market cap
-
P/E ratio
-$3.10
EPS
0.14
Beta
-
Dividend rate
Price and volume
Market cap
$186M
Beta
0.14
52-week high
$14.22
52-week low
$2.10
Average daily volume
1.1M
Financial strength
Current ratio
3.229
Quick ratio
3.034
Long term debt to equity
95.121
Total debt to equity
128.589
Interest coverage (TTM)
-25.24%
Management effectiveness
Return on assets (TTM)
-47.31%
Return on equity (TTM)
-136.87%
Valuation
Price to revenue (TTM)
12.665
Price to book
15.25
Price to tangible book (TTM)
15.25
Price to free cash flow (TTM)
-1.158
Growth
Earnings per share change (TTM)
-20.98%
3-year revenue growth (CAGR)
70.60%
3-year earnings per share growth (CAGR)
-15.66%
What the Analysts think about Verastem
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Verastem Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Verastem Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Verastem News
AllArticlesVideos
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Business Wire·6 days ago
Verastem: Preparing For Upcoming Catalysts
Seeking Alpha·4 weeks ago
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Verastem stock?
Verastem (VSTM) has a market cap of $186M as of December 24, 2024.
What is the P/E ratio for Verastem stock?
The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of December 24, 2024.
Does Verastem stock pay dividends?
No, Verastem (VSTM) stock does not pay dividends to its shareholders as of December 24, 2024.
When is the next Verastem dividend payment date?
Verastem (VSTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Verastem?
Verastem (VSTM) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.